Fervo Energy Q3 2026 EPS Tops Estimates at -$0.07, but Revenue Misses at $116K
Revenue of $116K vs. $136K expected and adjusted EPS of -$0.07 vs. -$0.09.
Fervo Energy (FRVO) posted mixed third-quarter 2026 results, with adjusted EPS above the estimate and revenue below it. Revenue was $116 thousand below the $136 thousand estimate, and adjusted EPS was -$0.07 above the -$0.09 estimate.
Shares rose 3.2% in premarket trading as of 7:03 a.m. ET, to $9.32 from a $9.03 close.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| Adjusted EPS | -$0.09 | -$0.07 | Beat by 21% |
| Revenue | $136K | $116K | Miss by 15% |
| Change | QoQ |
|---|---|
| Adjusted EPS | ▲ 82% |
| Revenue | ▲ 2.7% |
By our calculation, revenue was $20 thousand below the estimate and adjusted EPS was $0.02 above it. The QoQ column compares with the previous quarter's revenue of $113 thousand and adjusted EPS of -$0.38.
Track record
- EPS record. Adjusted EPS beat the estimate in 1 of the last 3 reports, including this one.
- Revenue record. Revenue beat the estimate in 0 of the last 3 reports.
- Revenue trend. Revenue over the last 3 reports, oldest first: $61 thousand, $113 thousand and $116 thousand.
What to watch
- Next-quarter estimates. Consensus calls for EPS of -$0.05 and revenue of $4.8 million next quarter, based on 6 analysts.
- Estimate record. Whether Fervo Energy returns to beating EPS estimates, which it did in 1 of its last 3 reports.
- Share reaction. How shares trade in the next regular session after the 3.2% gain in premarket trading.
- Related coverage. See our reports on Select Water Solutions, Ionis Pharmaceuticals, Affiliated Managers and Ocular Therapeutix.
Sources: Results are from Fervo Energy's Nov. 9, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Fervo Energy's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
Select Water Solutions Q3 2026 Revenue Tops Estimates at $412.2M, but EPS Misses at $0.16
EarningsIonis Pharmaceuticals Beats Q3 2026 Estimates as Revenue Rises 55% to $243.0M
EarningsAffiliated Managers Q3 2026 EPS Tops Estimates at $9.50, but Revenue Misses at $595.2M
EarningsOcular Therapeutix Misses Q3 2026 Estimates as Revenue Falls 11% to $12.9M
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.